Merck & Co., Inc. (FRA:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 188.48B |
| Revenue (ttm) | 54.17B |
| Net Income (ttm) | 13.97B |
| Shares Out | n/a |
| EPS (ttm) | 5.52 |
| PE Ratio | 13.49 |
| Forward PE | 9.78 |
| Dividend | 2.91 (3.92%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 3,273 |
| Average Volume | 2,403 |
| Open | 72.80 |
| Previous Close | 71.90 |
| Day's Range | 72.60 - 74.20 |
| 52-Week Range | 65.50 - 102.00 |
| Beta | n/a |
| RSI | 58.26 |
| Earnings Date | Oct 30, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Trump’s pharma strategy ‘holds Europe hostage’, Finnish MEP warns
Trump’s deals with Pfizer, AstraZeneca, and Merck expose risk to EU
Merck (MRK) Invests $3B in New Pharmaceutical Manufacturing Facility
Merck (MRK) Invests $3B in New Pharmaceutical Manufacturing Facility
Merck starts construction on $3B manufacturing plant in Virginia
Notable Monday Option Activity: MDGL, MRK, BHVN
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Madrigal Pharmaceuticals Inc (Symbol: MDGL), where a total of 1,259 contracts have traded s...
My Top 3 Pharma Stocks
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o...
Merck (MRK) Showcases Long-Term Survival Benefits of Keytruda in Lung Cancer Treatment
Merck (MRK) Showcases Long-Term Survival Benefits of Keytruda in Lung Cancer Treatment
US Supreme Court won't revive mumps vaccine antitrust case against Merck
The U.S. Supreme Court declined on Monday to hear a bid by a group of physicians and healthcare providers to revive their antitrust lawsuit accusing drugmaker Merck of misleading federal regulators to...
KEYTRUDA (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 ...
KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of...
Merck (MRK) Commences $3B Expansion of Virginia Facility
Merck (MRK) Commences $3B Expansion of Virginia Facility
Merck Starts Construction Of $3 Bln Manufacturing Facility At Its Elkton, Virginia Site
(RTTNews) - Merck & Co., Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Monday the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility...
Merck begins construction of $3 billion manufacturing facility in Virginia
Merck said on Monday it has begun construction of a $3 billion pharmaceutical manufacturing facility in Elkton, Virginia as part of its more than $70 billion investment to expand domestic manufacturin...
Merck breaks ground on $3B manufacturing plant in Virginia
Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion U.S. investment strategy.
Merck's (MRK) Keytruda Shows Promise in Combination with Cylembio for Melanoma
Merck's (MRK) Keytruda Shows Promise in Combination with Cylembio for Melanoma
Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia.
IO Biotech Reveals Positive Phase 3 Results For Cylembio Plus Keytruda In Advanced Melanoma
(RTTNews) - IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with Merck & Co Inc.'s (MRK)...
Merck (MRK) Reports Promising Keytruda Plus Padcev Results in Bladder Cancer Trial
Merck (MRK) Reports Promising Keytruda Plus Padcev Results in Bladder Cancer Trial
Merck (MRK) Showcases Promising Long-Term Benefits of Keytruda in Cancer Treatment
Merck (MRK) Showcases Promising Long-Term Benefits of Keytruda in Cancer Treatment
KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluat...
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE...
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of bladder cancer.
KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) reduced the risk ...
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortuma...
KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced long-term follow-up data continued to show durable benefit of KEYTRUDA (pembrolizumab), Merck’s anti-...
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial Carcinoma.